Institutional shares held 66.9 Million
7.9M calls
3.39M puts
Total value of holdings $2.67B
$315M calls
$135M puts
Market Cap $3.06B
76,688,496 Shares Out.
Institutional ownership 87.29%
# of Institutions 448


Latest Institutional Activity in VKTX

Top Purchases

Q2 2025
Norges Bank Shares Held: 1.77M ($70.5M)
Q2 2025
Two Sigma Investments, LP Shares Held: 1.31M ($52.4M)
Q2 2025
Two Sigma Advisers, LP Shares Held: 1.09M ($43.5M)
Q2 2025
Millennium Management LLC Shares Held: 942K ($37.5M)
Q2 2025
Citigroup Inc Shares Held: 864K ($34.4M)

Top Sells

Q2 2025
Alliancebernstein L.P. Shares Held: 25.8K ($1.03M)
Q2 2025
Citadel Advisors LLC Shares Held: 873K ($34.8M)
Q2 2025
Squarepoint Ops LLC Shares Held: 55.4K ($2.21M)
Q2 2025
National Bank Of Canada Shares Held: 122 ($4.86K)
Q2 2025
Exodus Point Capital Management, LP Shares Held: 38.7K ($1.54M)

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.


Insider Transactions at VKTX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
909K Shares
From 10 Insiders
Exercise of conversion of derivative security 456K shares
Grant, award, or other acquisition 452K shares
Open market or private purchase 1.24K shares
Sell / Disposition
857K Shares
From 6 Insiders
Open market or private sale 857K shares

Track Institutional and Insider Activities on VKTX

Follow Viking Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VKTX shares.

Notify only if

Insider Trading

Get notified when an Viking Therapeutics, Inc. insider buys or sells VKTX shares.

Notify only if

News

Receive news related to Viking Therapeutics, Inc.

Track Activities on VKTX